Clinical Trial Update: AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AlloNK, an allogeneic cord blood-derived NK cell therapy, in combination with Rituximab for relapsing B-cell–dependent rheumatologic di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathy
• Myositis
• Rheumatoid Arthritis
• Sjögren Syndrome
• Systemic Sclerosis

Drugs mentioned

• AlloNK
• Rituximab (rituximab)

Snippet

Sponsor: Artiva Biotherapeutics, Inc. | Conditions: Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs) | Phase 2 | Status: RECRUITING